PMS2 and cancer: The underlying genetic cause in patients who develop metachronous or synchronous cancers is not clear, germline mutations in MLH1 and MSH2 account for 90% of cases of HNPCC, with mutations in MSH6 and PMS2 accounting for the remainder (Giardiello et al, 2001).